Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
© 2024. The Author(s)..
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1-45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Leukemia - 38(2024), 4 vom: 29. Apr., Seite 712-719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dam, Merete [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3WJQ0SDW1A |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-024-02153-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367774720 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367774720 | ||
| 003 | DE-627 | ||
| 005 | 20240408232305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-024-02153-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM367774720 | ||
| 035 | |a (NLM)38287133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dam, Merete |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1-45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a pegaspargase |2 NLM | |
| 650 | 7 | |a 7D96IR0PPM |2 NLM | |
| 650 | 7 | |a Asparaginase |2 NLM | |
| 650 | 7 | |a EC 3.5.1.1 |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Centanni, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Friberg, Lena E |e verfasserin |4 aut | |
| 700 | 1 | |a Centanni, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Karlsson, Mats O |e verfasserin |4 aut | |
| 700 | 1 | |a Stensig Lynggaard, Line |e verfasserin |4 aut | |
| 700 | 1 | |a Johannsdottir, Inga Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Wik, Hilde Skuterud |e verfasserin |4 aut | |
| 700 | 1 | |a Malmros, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Vaitkeviciene, Goda Elizabeta |e verfasserin |4 aut | |
| 700 | 1 | |a Griskevicius, Laimonas |e verfasserin |4 aut | |
| 700 | 1 | |a Hallböök, Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Jónsson, Ólafur Gísli |e verfasserin |4 aut | |
| 700 | 1 | |a Overgaard, Ulrik |e verfasserin |4 aut | |
| 700 | 1 | |a Schmiegelow, Kjeld |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Stefan Nygaard |e verfasserin |4 aut | |
| 700 | 1 | |a Heyman, Mats |e verfasserin |4 aut | |
| 700 | 1 | |a Albertsen, Birgitte Klug |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 38(2024), 4 vom: 29. Apr., Seite 712-719 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:4 |g day:29 |g month:04 |g pages:712-719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-024-02153-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 4 |b 29 |c 04 |h 712-719 | ||